While research suggests having a higher weight may increase your risk for certain conditions, people can be healthy at every ...

Despite the popularity of semaglutide drugs like Ozempic and Wegovy for weight loss, surveys suggest that most people still ...

Respondents see the glucagon-like peptide 1 (GLP-1) drugs as a major advance. They also have concerns about whether insurers ...

Patients with diabetes mellitus who use GLP-1 RAs have an increased risk for acute and chronic pancreatitis, according to a study presented at DDW 2025.

In 'Diet, Drugs, and Dopamine,' former FDA Commissioner David A. Kessler offers a comprehensive guide to weight loss.

The ability to predict side effects such as nausea before starting treatment represents a paradigm shift in precision ...

Vida Health announced outcomes from its Clinical Obesity Management Program, which demonstrate that most patients do not ...

GLP-1s are the main reason why pharmacy expenditures have reached double digits in 2025, a continuing trend from 2024, ...

Glucagon-like peptide-1 receptor agonists are tied to a reduction in alcohol intake in patients being treated for obesity.

First-generation GLP-1 drugs have found to cut down the risk of obesity-related cancers by 41%, outperforming weight-loss ...

Menopausal hormone treatment (MHT) might indirectly help with weight loss by improving sleep and redistributing abdominal fat ...